As part of the settlement, Stimwave has agreed to cease commercialization of all high frequency spinal cord stimulation systems, globally, in exchange for dismissal of the lawsuit with no damages assessed. The settlement pertains exclusively to spinal cord stimulation (SCS) and does not affect in any way Stimwave’s commercialization of its peripheral nerve stimulation (PNS) products for chronic pain management.
